Weekly / Vol. 68 / No. 12

Morbidity and Mortality Weekly Report

March 29, 2019

Enterovirus D68-Associated Acute Respiratory Illness — New Vaccine Surveillance Network, United States, July-October, 2017 and 2018

Stephanie A. Kujawski, PhD^{1,2}; Claire M. Midgley, PhD²; Brian Rha, MD²; Joana Y. Lively, MPH^{2,3}; W. Allan Nix²; Aaron T. Curns, MPH²; Daniel C. Payne, PhD²; Janet A. Englund, MD⁴; Julie A. Boom, MD^{5,6}; John V. Williams, MD⁷; Geoffrey A. Weinberg, MD⁸; Mary A. Staat, MD⁹; Rangaraj Selvarangan, PhD¹⁰; Natasha B. Halasa, MD¹¹; Eileen J. Klein, MD⁴; Leila C. Sahni, PhD⁵; Marian G. Michaels, MD⁷; Lynne Shelley⁸; Monica McNeal, MS⁹; Christopher J. Harrison, MD¹⁰; Laura S. Stewart, PhD¹¹; Adriana S. Lopez, MHS²; Janell A. Routh, MD²; Manisha Patel, MD²; M. Steven Oberste, PhD²; John T. Watson, MD²; Susan I. Gerber, MD²

In the fall of 2014, an outbreak of enterovirus D68 (EV-D68)-associated acute respiratory illness (ARI) occurred in the United States (1,2); before 2014, EV-D68 was rarely reported to CDC (2,3). In the United States, reported EV-D68 detections typically peak during late summer and early fall (3). EV-D68 epidemiology is not fully understood because testing in clinical settings seldom has been available and detections are not notifiable to CDC. To better understand EV-D68 epidemiology, CDC recently established active, prospective EV-D68 surveillance among pediatric patients at seven U.S. medical centers through the New Vaccine Surveillance Network (NVSN) (4). This report details a preliminary characterization of EV-D68 testing and detections among emergency department (ED) and hospitalized patients with ARI at all NVSN sites during July 1-October 31, 2017, and the same period in 2018. Among patients with ARI who were tested, EV-D68 was detected in two patients (0.8%) in 2017 and 358 (13.9%) in 2018. Continued active, prospective surveillance of EV-D68-associated ARI is needed to better understand EV-D68 epidemiology in the United States.

NVSN conducts active, prospective, population-based surveillance for ARI* among children and teens aged <18 years at seven U.S. medical centers at Cincinnati, Ohio; Houston, Texas; Kansas City, Missouri; Nashville, Tennessee; Pittsburgh,

Pennsylvania; Rochester, New York; and Seattle, Washington (4). Respiratory specimens (mid-turbinate nasal, oropharyngeal swabs, or both) from patients with ARI were tested at each site for EV-D68 using a validated real-time reverse transcription—polymerase chain reaction assay. Two NVSN sites (Nashville and Pittsburgh) tested all ARI specimens for EV-D68 directly. Five sites (Cincinnati, Houston, Kansas City, Rochester, and Seattle) used a two-step algorithm, wherein all ARI specimens were first tested for enterovirus/rhinovirus (EV/RV) using molecular diagnostic assays approved by the Food and Drug Administration or CDC; all EV-positive or RV-positive specimens were subsequently tested for EV-D68. Demographic and admission status information were collected from medical charts. EV-D68 detections were analyzed by year, month, site, admission status, and patient sex and age.

INSIDE

- 281 Imported Toxin-Producing Cutaneous
 Diphtheria Minnesota, Washington, and New
 Mexico, 2015–2018
- 285 Candida Bloodstream Infections Among Persons Who Inject Drugs — Denver Metropolitan Area, Colorado, 2017–2018
- 289 Notes from the Field: Investigation of Colorado Tick Fever Virus Disease Cases Oregon, 2018
- 292 QuickStats

Continuing Education examination available at https://www.cdc.gov/mmwr/cme/conted_info.html#weekly.



^{*}A child (aged <18 years) was eligible for inclusion in NVSN ARI surveillance if he or she visited the emergency department or were admitted to the hospital in the 48 hours preceding enrollment, with one or more of the following symptoms/ events: fever; cough; earache; nasal congestion; runny nose; sore throat; vomiting after coughing; wheezing; shortness of breath/rapid or shallow breathing; apnea; apparent life-threatening event or brief resolved unexplained event; or myalgias and the duration of illness at the time of enrollment was <14 days. Children with a known nonrespiratory cause for hospitalization/ED visit were excluded from enrollment, as were children residing outside the surveillance area.

Based on preliminary data, test results were positive for EV-D68 for two (0.08%) of 2,433 patients with ARI who were tested during 2017 and 358 (13.9%) of 2,579 tested during 2018. In 2017, one patient whose test result was positive for EV-D68 was hospitalized in Houston, and one was evaluated in the ED in Rochester. In 2018, patients with EV-D68-positive test results were identified at all seven sites, and 242 of 358 patients (67.6%) were hospitalized (range by site = 53.3%-76.8%) (Table). EV-D68 was detected in 9.2% of patients with ED visits for ARI and 18.3% of hospitalized patients with ARI. Approximately half (169; 47.2%) of the 2018 EV-D68 detections occurred in September (Figure). The peak of detections varied by site, with Cincinnati and Kansas City peaking in late August through September; Houston, Pittsburgh, and Rochester in mid-September; and Nashville and Seattle in October. The median age of patients testing positive for EV-D68 was 3 years (range = 1 month-17 years; interquartile range = 1.5–5 years), and 211 (58.9%) were male. Among 42 EV-D68–positive specimens from 2018 sequenced at CDC, all were lineage B3.

Discussion

During 2018, ARI surveillance through NVSN detected EV-D68 at levels substantially higher than those during the same period in 2017. European countries also reported EV-D68 activity in 2018 (5,6). Although EV-D68 infection more commonly causes respiratory illness, previous investigations have suggested that EV-D68 might also be

Summary

What is already known about this topic?

A nationwide outbreak of enterovirus D68 (EV-D68), which is associated with acute respiratory illness (ARI), occurred in 2014. EV-D68 epidemiology is not fully understood because testing in clinical settings is limited and reporting to CDC is voluntary.

What is added by this report?

Based on active, prospective surveillance of ARI through the New Vaccine Surveillance Network, EV-D68 was detected in two (0.8%) patients in 2017 and 358 (13.9%) in 2018. Detections in 2018 peaked in September.

What are the implications for public health practice?

Continued active, prospective surveillance is needed to better understand trends in EV-D68 circulation.

associated with acute flaccid myelitis (AFM), a rare neurologic condition characterized by acute flaccid limb weakness (7,8). Contemporaneous with the 2014 outbreak of EV-D68 associated with respiratory illness, CDC received increased reports of AFM, supporting a temporal association between EV-D68 and AFM (7). Since 2015, CDC has conducted surveillance for AFM in the United States using a standardized case definition (9). As of March 1, 2019, CDC has confirmed 223 AFM cases in 2018, with peak onset of limb weakness in September 2018; in 2017, CDC confirmed 35 cases (8,10). Although AFM is rare in the United States, these AFM surveillance data, along with the EV-D68 activity documented

The MMWR series of publications is published by the Center for Surveillance, Epidemiology, and Laboratory Services, Centers for Disease Control and Prevention (CDC), U.S. Department of Health and Human Services, Atlanta, GA 30329-4027.

Suggested citation: [Author names; first three, then et al., if more than six.] [Report title]. MMWR Morb Mortal Wkly Rep 2019;68:[inclusive page numbers].

Centers for Disease Control and Prevention

Robert R. Redfield, MD, Director
Anne Schuchat, MD, Principal Deputy Director
Chesley L. Richards, MD, MPH, Deputy Director for Public Health Science and Surveillance
Rebecca Bunnell, PhD, MEd, Director, Office of Science
Barbara Ellis, PhD, MS, Acting Director, Office of Science Quality, Office of Science
Michael F. Iademarco, MD, MPH, Director, Center for Surveillance, Epidemiology, and Laboratory Services

MMWR Editorial and Production Staff (Weekly)

Charlotte K. Kent, PhD, MPH, Editor in Chief
Jacqueline Gindler, MD, Editor
Mary Dott, MD, MPH, Online Editor
Teresa F. Rutledge, Managing Editor
Douglas W. Weatherwax, Lead Technical Writer-Editor
Glenn Damon, Soumya Dunworth, PhD, Teresa M. Hood, MS,
Technical Writer-Editors

Matthew L. Boulton, MD, MPH
Virginia A. Caine, MD
Katherine Lyon Daniel, PhD
Jonathan E. Fielding, MD, MPH, MBA
David W. Fleming, MD
William E. Halperin, MD, DrPH, MPH

MMWR Editorial Board

Timothy F. Jones, MD, *Chairman*Robin Ikeda, MD, MPH
Phyllis Meadows, PhD, MSN, RN
Jewel Mullen, MD, MPH, MPA
Jeff Niederdeppe, PhD
Patricia Quinlisk, MD, MPH

Martha F. Boyd, *Lead Visual Information Specialist*Maureen A. Leahy, Julia C. Martinroe,
Stephen R. Spriggs, Tong Yang, *Visual Information Specialists*Quang M. Doan, MBA, Phyllis H. King,
Terraye M. Starr, Moua Yang, *Information Technology Specialists*


Stephen C. Redd, MD Patrick L. Remington, MD, MPH Carlos Roig, MS, MA William Schaffner, MD Morgan Bobb Swanson, BS

TABLE. Number of patients with acute respiratory illness (ARI) who were tested and received results positive for EV-D68, by admission status and network surveillance site — New Vaccine Surveillance Network (NVSN), United States, July 1–October 31, 2018

Admission status/NVSN site	No. of ARI patients tested	No. (%) of EV/RV-positive patients	EV-D68-positive patients		
			No. of patients	% Among EV/RV- positive patients	% Among ARI patients tested
Emergency department visit					
Cincinnati	148	40 (27.0)	13	32.5	8.8
Houston	157	58 (36.9)	9	15.5	5.7
Kansas City	306	163 (53.3)	21	12.9	6.9
Nashville	282	N/A	21	N/A	7.4
Pittsburgh	198	N/A	25	N/A	12.6
Rochester	61	34 (55.7)	18	52.9	29.5
Seattle	104	73 (70.2)	9	12.3	8.7
All sites	1,256	368 (47.4)*	116	19.0 [†]	9.2
Inpatient					
Cincinnati	235	102 (43.4)	43	42.2	18.3
Houston	220	62 (28.2)	16	25.8	7.3
Kansas City	139	92 (66.2)	33	35.9	23.7
Nashville	202	N/A	24	N/A	11.9
Pittsburgh	269	N/A	70	N/A	26.0
Rochester	161	108 (67.1)	45	41.7	28.0
Seattle	97	58 (59.8)	11	19.0	11.3
All sites	1,323	422 (49.5)*	242	35.1 [†]	18.3
Total	2,579	790 (48.5)*	358	27.6 [†]	13.9

Abbreviations: EV = enterovirus; N/A = not applicable; RV = rhinovirus.

FIGURE. Enterovirus-D68 (EV-D68) detections, by date of specimen collection and surveillance network site (N = 358) — New Vaccine Surveillance Network, United States, July 1–October 31, 2018



through NVSN, provide additional supporting evidence for a temporal association between EV-D68 respiratory illness and AFM. CDC, in collaboration with clinical and public health partners, continues to investigate the relationship between AFM and enteroviruses, including EV-D68.

The findings in this report are subject to at least two limitations. First, this report describes EV-D68 testing within NVSN during July–October of each year, but additional cases likely occurred outside this period in 2018. Therefore, the results might not be representative of the entire EV-D68 season.

^{*} These percentages only include ARI patients at sites that first tested for EV/RV (Cincinnati, Houston, Kansas City, Seattle, and Rochester). For comparison, in 2017, a total of 715 of 1,714 (41.7%) ARI patients first tested positive for EV/RV.

[†] These percentages only include EV-D68-positive patients at sites that first tested for EV/RV (Cincinnati, Houston, Kansas City, Seattle, and Rochester. For comparison, in 2017, two of 715 (0.3%) EV/RV-positive patients tested positive for EV-D68.

Second, NVSN sentinel surveillance sites are geographically varied, but might not be representative of all regions of the United States.

Through recently established active, prospective, ARI surveillance in NVSN, EV-D68 was detected in 0.8% of patients tested in 2017 and 13.9% in 2018. Continued surveillance for EV-D68–associated ARI is needed to better understand the epidemiology of EV-D68 in the United States.

Corresponding author: Stephanie A. Kujawski, skujawski@cdc.gov, 404-718-7173.

¹Epidemic Intelligence Service, CDC; ²Division of Viral Diseases, National Center for Immunization and Respiratory Diseases, CDC; ³IHRC, Atlanta, GA; ⁴Seattle Children's Hospital, Seattle, Washington; ⁵Texas Children's Hospital, Houston, Texas; ⁶Baylor College of Medicine, Houston, Texas; ⁷UPMC Children's Hospital of Pittsburgh, Pittsburgh, Pennsylvania; ⁸University of Rochester School of Medicine and Dentistry, Rochester, New York; ⁹Department of Pediatrics, University of Cincinnati College of Medicine, Division of Infectious Diseases, Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio; ¹⁰The Children's Mercy Hospital, Kansas City, Missouri; ¹¹Vanderbilt University Medical Center, Nashville, Tennessee.

All authors have completed and submitted the ICMJE form for disclosure of potential conflicts of interest. W. Allan Nix reports a CDC employee invention report filing with CDC's Technology Transfer Office for the pan EV-D68 real time reverse transcription—polymerase chain reaction assay and U.S. Patent Numbers 7247457, 7714122, and 8048630. W. Allan Nix and M. Steven Oberste report issuance of U.S. patent number 9,938,588 (Compositions and methods for detecting enterovirus D68). John Williams reports personal fees from Quidel and from GlaxoSmithKline, outside the submitted work. No other potential conflicts of interest were disclosed.

References

- Biggs HM, McNeal M, Nix WA, et al. Enterovirus D68 infection among children with medically attended acute respiratory illness, Cincinnati, Ohio, July–October 2014. Clin Infect Dis 2017;65:315–23. https:// doi.org/10.1093/cid/cix314
- Midgley CM, Watson JT, Nix WA, et al.; EV-D68 Working Group. Severe respiratory illness associated with a nationwide outbreak of enterovirus D68 in the USA (2014): a descriptive epidemiological investigation. Lancet Respir Med 2015;3:879–87. https://doi. org/10.1016/S2213-2600(15)00335-5
- 3. Khetsuriani N, Lamonte-Fowlkes A, Oberst S, Pallansch MA. Enterovirus surveillance—United States, 1970–2005. MMWR Surveill Summ 2006;55(No. SS-8).
- CDC. New Vaccine Surveillance Network (NVSN). Atlanta, GA: US Department of Health and Human Services, CDC; 2017. https://www.cdc.gov/surveillance/nvsn/index.html
- The United Kingdom Acute Flaccid Paralysis Afp Task Force. An increase in reports of acute flaccid paralysis (AFP) in the United Kingdom, 1 January 2018–21 January 2019: early findings. Euro Surveill 2019;24:1900093.
- Pellegrinelli L, Giardina F, Lunghi G, et al. Emergence of divergent enterovirus (EV) D68 sub-clade D1 strains, northern Italy, September to October 2018. Euro Surveill 2019;24:1900090. https://doi. org/10.2807/1560-7917.ES.2018.24.7.1900090
- 7. Sejvar JJ, Lopez AS, Cortese MM, et al. Acute flaccid myelitis in the United States, August–December 2014: results of nationwide surveillance. Clin Infect Dis 2016;63:737–45. https://doi.org/10.1093/cid/ciw372
- 8. CDC. Acute flaccid myelitis. Atlanta, GA: US Department of Health and Human Services, CDC; 2019. https://www.cdc.gov/acute-flaccid-myelitis/index.html
- 9. Infectious Disease Committee, Council of State and Territorial Epidemiologists. Revision to the standardized surveillance and case definition for acute flaccid myelitis, position statement 17-ID-01. Atlanta, GA: Council of State and Territorial Epidemiologists; 2017. https://c.ymcdn.com/sites/www.cste.org/resource/resmgr/2017PS/2017PSFinal/17-ID-01.pdf
- 10. McKay SL, Lee AD, Lopez AS, et al. Increase in acute flaccid myelitis— United States, 2018. MMWR Morb Mortal Wkly Rep 2018;67:1273–5. https://doi.org/10.15585/mmwr.mm6745e1